Jacobs Levy Equity Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-28,791
| Closed | -$32K | – | 1097 |
|
|
2022
Q4 | $32K | Sell |
28,791
-1,559
| -5% | -$1.73K | ﹤0.01% | 932 |
|
|
2022
Q3 | $71K | Sell |
30,350
-247,681
| -89% | -$579K | ﹤0.01% | 962 |
|
|
2022
Q2 | $842K | Sell |
278,031
-37,835
| -12% | -$115K | 0.01% | 785 |
|
|
2022
Q1 | $2.15M | Buy |
315,866
+48,834
| +18% | +$332K | 0.01% | 611 |
|
|
2021
Q4 | $2.23M | Buy |
+267,032
| New | +$2.23M | 0.01% | 599 |
|
|
2021
Q3 | – | Sell |
-126,857
| Closed | -$863K | – | 1156 |
|
|
2021
Q2 | $863K | Sell |
126,857
-1,128
| -0.9% | -$7.67K | 0.01% | 768 |
|
|
2021
Q1 | $1.31M | Buy |
127,985
+27,242
| +27% | +$280K | 0.01% | 680 |
|
|
2020
Q4 | $705K | Sell |
100,743
-82,094
| -45% | -$574K | 0.01% | 800 |
|
|
2020
Q3 | $1.49M | Buy |
182,837
+2,089
| +1% | +$17K | 0.02% | 572 |
|
|
2020
Q2 | $1.25M | Buy |
180,748
+5,999
| +3% | +$41.4K | 0.01% | 626 |
|
|
2020
Q1 | $830K | Buy |
174,749
+37,854
| +28% | +$180K | 0.01% | 670 |
|
|
2019
Q4 | $1.2M | Buy |
136,895
+53,729
| +65% | +$469K | 0.01% | 651 |
|
|
2019
Q3 | $277K | Buy |
83,166
+21,400
| +35% | +$71.3K | ﹤0.01% | 793 |
|
|
2019
Q2 | $306K | Buy |
61,766
+46,266
| +298% | +$229K | ﹤0.01% | 812 |
|
|
2019
Q1 | $96K | Buy |
+15,500
| New | +$96K | ﹤0.01% | 931 |
|